Interferons

• Development of Sarcoidosis Following Completion of Treatment for Hepatitis C with Pegylated Interferon-α2a and Ribavirin: A Case Report and Literature Review

  Albéric-Rembrandt Gayet, Patrick Plaisance, Jean-François Bergmann and Stéphane Mouly

  • Clinical Medicine & Research December 2010, 8 (3-4)163-167;
  • DOI: https://doi.org/10.3121/cmr.2010.886
• Could a Six-Month Course of Pegylated Interferon-α2a and Ribavirin for Hepatitis Virus C Trigger Sarcoidosis? A Case Report and Literature Review

  Albéric-Rembrandt Gayet, Patrick Plaisance, Jean- François Bergmann and Stéphane Mouly

  • Clinical Medicine & Research September 2010, cmr.2010.886;
  • DOI: https://doi.org/10.3121/cmr.2010.886
• Could a Six-Month Course of Pegylated Interferon-α2a and Ribavirin for Hepatitis Virus C Trigger Sarcoidosis? A Case Report and Literature Review

  Albéric-Rembrandt Gayet, Patrick Plaisance, Jean-François Bergmann and Stéphane Mouly

  • Clinical Medicine & Research September 2010, cmr.2010.886;
  • DOI: https://doi.org/10.3121/cmr.2010.886
• Multiple Sclerosis: It’s Not The Disease You Thought It Was

  Loren A. Rolak

  • Clinical Medicine & Research January 2003, 1 (1)57-60;
  • DOI: https://doi.org/10.3121/cmr.1.1.57
• Testing for Latent Tuberculosis

  Asad Ayub, Steven H. Yale, Kurt D. Reed, Rana M. Nasser and Steven R. Gilbert

  • Clinical Medicine & Research August 2004, 2 (3)191-194;
  • DOI: https://doi.org/10.3121/cmr.2.3.191
• Insight into Multiple Sclerosis

  Kelli Wehman-Tubbs, Steven H. Yale and Loren A. Rolak

  • Clinical Medicine & Research February 2005, 3 (1)41-44;
  • DOI: https://doi.org/10.3121/cmr.3.1.41